WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company ...
Tsukuba, Japan—The human genome contains approximately 1,600 types of transcription factors responsible for regulating gene activity across more than 400 tissue and cell types. Chromatin ...
Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback